Article
Modeling the PAX5P80R Mutation Reveals HIF2α Activation as a Common Feature and Therapeutic Target in B-cell Acute Lymphoblastic Leukemia.
Cancer research - 1 Aug 2025
Bayet Manon, Fregona Vincent, Bouttier Mathieu, Rouzier Clémence, Bigot Jérémy, Jamrog Laura, Hebrard Sylvie, Prade Naïs, Lagarde Stéphanie, Didier Christine, Gachet Stéphanie, Passet Marie, Largeaud Laetitia, Pasquet Marlène, Khamlichi Ahmed Amine, Clappier Emmanuelle, Delabesse Eric, Broccardo Cyril, Gerby Bastien
Abstract excerpt
The transcription factor PAX5 is a major target of genetic alterations in human B-cell precursor acute lymphoblastic leukemia (B-ALL). Among the alterations, the P80R mutation affecting the DNA-binding domain represents the most frequent PAX5 point mutation in B-ALL. In contrast to other somatic PAX5 mutations, PAX5P80R defines a distinct B-ALL subtype characterized by a unique transcriptional program. In this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.